USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

SAN DIEGO--(BUSINESS WIRE)-- Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin. The Patent Office determined that multiple examples of prior art render claims 1 and 24 unpatentable.

“We are pleased, but not surprised, to see this action from the USPTO,” said Bob Rogers, CEO of Kurin, Inc. “We strongly believe that we do not infringe the ‘483 patent, but also believe the patent was preceded by other inventions that should render it invalid. This first office action suggests that the Patent Office confirms our belief.

“This USPTO action follows the recent Court order on the ongoing litigation where the Court opined that Kurin was likely to prevail on its noninfringement motion on Claim 1 and possibly Claim 24 as well. We make no assumptions as to the conclusion of these parallel paths, but remain confident that we are on the correct side of this issue and look forward to a successful outcome through both the Court and the USPTO.”

Kurin’s revolutionary 510(k) cleared approaches to the contaminated blood culture problem are based on elegantly simple, intuitive designs that require no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

About Kurin, Inc.

Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230815822924/en/